CureDuchenne Wins STRIVE Award to Expand Services for DMD Community

Charles Moore avatar

by Charles Moore |

Share this article:

Share article via email
CureDuchenne award

cureduchennelogoCureDuchenne, the Duchenne muscular dystrophy nonprofit  group engaged in disease advocacy and research funding,  announced on Sept. 7 — World Duchenne Awareness Day 2016 — that it has received a coveted STRIVE Award in recognition of its efforts.

The awards were created by PTC Therapeutics to recognize, support, and honor Duchenne advocacy organizations, and the grant money is used to facilitate ideas or programs that will benefit patients and families within the Duchenne muscular dystrophy (DMD) community. Its grants

millerd“We are delighted to have won this STRIVE Award, which will help us make a huge difference in the lives of people affected by Duchenne muscular dystrophy,” Debra Miller, CureDuchenne co-founder and CEO, said in a press release. “This will help us launch an online information and networking portal to provide valuable information and support for the families and caregivers of those with Duchenne, and we can’t wait to get started.”


CureDuchenne was one of four organizations to receive STRIVE Awards (Strategies to Realize Innovation, Vision and Empowerment) this year, out of entries received from 26 organizations across 15 countries. STRIVE Award winners are chosen in a competitive process, with all applications reviewed by an independent, external panel of experts with knowledge in rare diseases, patient advocacy, and funding initiatives. Entries are judged based on criteria such as feasibility, creativity, budget, impact, and sustainability. The awards are for one year.

The STRIVE Award will support organization’s launch of a Virtual Durable Medical Equipment Expo, an interactive education and networking website to provide DMD caregivers and family members with up-to-date, unbiased information, as well as reviews on a wide range of mobility equipment to help keep patients remain mobile and active longer.

Founded in 2003, CureDuchenne’s central focus is saving the lives of people with Duchenne muscular dystrophy, which affects more than 300,000 children and young adults worldwide. Nine CureDuchenne supported research projects have advanced to human clinical trials. CureDuchenne also helps to bring physical therapy and standard of care to local communities across the U.S. through its CureDuchenne Cares program.

PTC Therapeutics, Inc.